96
Our group and others have identified novel coumarin compounds with anti-proliferative and/or 97 cytotoxic activity on cancer cells, depending on their substitution pattern (Riveiro, 2010) .
98
Specifically, in previous publications, we reported the significant inhibitory activity of certain
99
coumarins on the proliferation of leukemic cell lines (Riveiro, 2004 (Riveiro, , 2008a (Riveiro, , b and 2009 . In addition,
100
we described that such inhibitory effects could be related to either differentiating (Riveiro, 2004, 
107
there is no published report on the anti-cancer activity of prenylated coumarins. Thus, aiming to 108 extend our previous research, in the present work we performed a screening of six natural 109 prenylated coumarins isolated from Toddalia asiatica for potential effects on U-937 cell proliferation,
110
viability and differentiation, as well as for pro-apoptotic activity. 
152
The structures of these compounds were determined using 2D NMR and EIMS techniques, and
153
confirmed by comparison of spectroscopic data for the compounds isolated against literature data
154
(Sharma, 1981).
155
The coumarin 5,7-dimethoxy-4-methylcoumarin (7; 
11
The synthetic compound 5,7-dimethoxy-4-methylcoumarin (7) was also tested in order to 278 evaluate the influence of the 5,7-dimethoxy substitution pattern in the anti-proliferative and cytotoxic
279
activities of the coumarins under study herein. As shown in Table 1 
283
Subsequently, a series of experiments were conducted in order to better characterize the anti-
284
proliferative effects observed for toddaculin (6). 
301
Apoptotic and necrotic cells were detected by studying chromatin condensation with HO test and 302 nuclear staining with PI. Figure 3 .D shows that apoptosis was the prevailing form of cell death
303
induced by toddaculin (6) at lower concentrations than 500 µM, whereas necrosis was negligible.
304
However, when cells were exposed to higher concentrations of toddaculin (6), the percentage of 12 necrotic cells increased significantly, suggesting that toddaculin (6) is capable of inducing apoptosis 306 or necrosis in U-937 cells depending on the concentration.
307
In subsequent experiments, the effect of toddaculin (6) treatment on the activation of caspase-3,
308
a key enzyme involved in the programmed cell death process, was evaluated. Toddaculin (6) was 
320
The pro-apoptotic activity of toddaculin (6) in U-937 cells entails down-regulation of p-ERK and 321 p-Akt but not p-JNK or p-p38.
323
The treatment of U-937 cells with toddaculin (6; 250 µM) for up to 24 h had no effect on JNK or 
353
The pro-apoptotic activity of toddaculin (6) involved a rapid down regulation of both p-Akt and p- 
369
Another reason why toddaculin (6) should be viewed as an interesting compound for novel anti-
370
leukemic drug design is that it induces apoptosis in a p53-independent manner, this argument is 371 based on the fact that U-937 cells are p53-defficient. Often, cancer cells develop resistance to a
372
given chemotherapeutic agent when it exerts pro-apoptotic effects through the p53 pathway. Thus, 373 the development of new drugs which act in a p53-independent form would constitute a novel 374 therapeutic strategy for overcoming multidrug-resistance in leukemia.
375
Our group and others have described the differentiating activity of certain coumarins in different 
391
Our results also provide evidence of a correlation between some structural properties of 392 toddaculin (6) and its anti-leukemic activities in vitro. Findings obtained for coumarin 7 during the 393 present research point out that the methoxyl groups at positions 5 and 7 would not be involved in 394 the pro-apoptotic or differentiating effects of toddaculin (6) in U-937 cells. On the other hand, our 395 data illustrate the key role of the prenyl residue at position 6 for both activities. Of note, aeculeatin
396
(1), coumarin 2, toddanol (4) and toddalactone (5) also have a prenyl residue at position 6, and the 397 substituent at C-6 of coumarin 2 is very similar to that of toddaculin (6). However, the latter was the 398 unique compound of the series with pro-apoptotic activity. These observations emphasize the direct 399 relationship between the cited residue and the pharmacological activities of toddaculin (6). Thus,
400
future structure-activity relationship studies of toddaculin (6) should be based on this portion of the 401 molecule.
402
In conclusion, this is the first report describing the dual pharmacological profile of toddacullin (6 
460
(1), 154-164.
461
Laurin, P., Ferroud, D., Klich, M., Dupuis-Hamelin, C., Mauvais, P., Lassaigne, P., Bonnefoy, A., 
531
ANOVA test (p < 0.01) was performed followed by SNK a posteriori test (**p < 0.01; ***p < 0.001).
532
Significant differences were evaluated respect to vehicle control group (data not shown) at each 
